These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9867740)

  • 21. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism.
    Fitzsimmons ME; Collins JM
    Drug Metab Dispos; 1997 Feb; 25(2):256-66. PubMed ID: 9029057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.
    Boffito M; Dickinson L; Hill A; Back D; Moyle G; Nelson M; Higgs C; Fletcher C; Mandalia S; Gazzard B; Pozniak A
    Antivir Ther; 2004 Jun; 9(3):423-9. PubMed ID: 15259905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir.
    Taylor S; Back DJ; Drake SM; Workman J; Reynolds H; Gibbons SE; White DJ; Pillay D
    J Antimicrob Chemother; 2001 Sep; 48(3):351-4. PubMed ID: 11532998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients.
    Gieschke R; Fotteler B; Buss N; Steimer JL
    Clin Pharmacokinet; 1999 Jul; 37(1):75-86. PubMed ID: 10451784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
    Boffito M; Back D; Stainsby-Tron M; Hill A; Di Perri G; Moyle G; Nelson M; Tomkins J; Gazzard B; Pozniak A
    Br J Clin Pharmacol; 2005 Jan; 59(1):38-42. PubMed ID: 15606438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review.
    van Maarseveen EM; Rogers CC; Trofe-Clark J; van Zuilen AD; Mudrikova T
    AIDS Patient Care STDS; 2012 Oct; 26(10):568-81. PubMed ID: 23025916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
    Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
    Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic considerations in the therapeutic application of cyclosporine in renal transplantation.
    Kahan BD
    Transplant Proc; 1996 Aug; 28(4):2143-6. PubMed ID: 8769182
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacology of antiretroviral drugs.
    Hoetelmans RM
    Antivir Ther; 1999; 4 Suppl 3():29-41. PubMed ID: 16021869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women.
    Martinez-Rebollar M; Lonca M; Perez I; Soy D; Brunet M; Martin R; Coll O; Hernandez S; Laguno M; Milinkovic A; Larrousse M; Calvo M; Blanco JL; Martínez E; Gatell JM; Mallolas J
    Ther Drug Monit; 2011 Dec; 33(6):772-7. PubMed ID: 22105596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal transplantation in an HIV-infected patient: pharmacokinetic aspects.
    Alstrup K; Kangas I; Laursen AL; Jørgensen KA
    Scand J Urol Nephrol; 2011 Apr; 45(3):216-9. PubMed ID: 21222566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir.
    Kurowski M; Müller M; Donath F; Mrozikiewicz M; Möcklinghoff C
    Eur J Med Res; 1999 Mar; 4(3):101-4. PubMed ID: 10085276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Garlic supplements can impede HIV medication.
    J Am Coll Surg; 2002 Feb; 194(2):251. PubMed ID: 11848645
    [No Abstract]   [Full Text] [Related]  

  • 34. Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection.
    Perry CM; Noble S
    Drugs; 1998 Mar; 55(3):461-86. PubMed ID: 9530549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes.
    Ye ZW; Camus S; Augustijns P; Annaert P
    Biopharm Drug Dispos; 2010 Mar; 31(2-3):178-88. PubMed ID: 20238377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes of kidney transplantation in HIV-infected recipients.
    van Maarseveen EM; van Zuilen AD; Mudrikova T
    N Engl J Med; 2011 Feb; 364(7):683; author reply 684. PubMed ID: 21323551
    [No Abstract]   [Full Text] [Related]  

  • 37. Examining pharmacodynamic and pharmacokinetic properties of eleven analogues of saquinavir for HIV protease inhibition.
    Jayaswal A; Mishra H; Mishra A; Shah K
    Arch Virol; 2019 Apr; 164(4):949-960. PubMed ID: 30680529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gender: a possible determinant in dosing of dermatologic drugs--an overview.
    Modjtahedi BS; Modjtahedi SP; Maibach HI
    Cutan Ocul Toxicol; 2006; 25(3):195-210. PubMed ID: 16980245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Saquinavir: a review of its use in boosted regimens for treating HIV infection.
    Plosker GL; Scott LJ
    Drugs; 2003; 63(12):1299-324. PubMed ID: 12790697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors.
    Washington CB; Flexner C; Sheiner LB; Rosenkranz SL; Segal Y; Aberg JA; Blaschke TF;
    Clin Pharmacol Ther; 2003 May; 73(5):406-16. PubMed ID: 12732841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.